ETR:AFX Carl Zeiss Meditec (AFX) Stock Price, News & Analysis → Strange new buyer driving up gold (From Stansberry Research) (Ad) Free AFX Stock Alerts €97.65 +1.10 (+1.14%) (As of 04/18/2024 ET) Add Compare Share Share Today's Range€94.80▼€97.9550-Day Range€102.00▼€121.9552-Week Range€72.60▼€128.50Volume144,151 shsAverage Volume94,405 shsMarket Capitalization$8.73 billionP/E Ratio31.50Dividend Yield1.13%Price TargetN/A Stock AnalysisStock AnalysisChartHeadlinesStock AnalysisChartHeadlines Get Carl Zeiss Meditec alerts: Email Address Ad Gold Safe ExchangeThe “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide! About Carl Zeiss Meditec Stock (ETR:AFX)Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, such as ametropia (refraction), cataracts, glaucoma, and renital disorders. This segment also provides devices for general ophthalmological examination and care, including slit lamps, refractometers, tonometers, optical coherence tomography devices, and fundus cameras; and devices for functional diagnostics (perimeters), as well as digital products for storage, evaluation, and sharing of clinical data. In addition, this segment offers surgical ophthalmology products comprising surgical microscopes, biometers, phacoemulsification, and vitrectomy devices; intraocular lenses for cataract patients; and systems and consumables for laser eye surgery. The Microsurgery segment provides products and solutions for invasive surgical treatments; and solutions in the area of ear, nose and throat, plastic and reconstructive, neuro, dental, and spinal surgeries. It serves physicians in various fields and hospitals. The company was founded in 1846 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG is a subsidiary of Carl Zeiss AG.Read More AFX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AFX Stock News HeadlinesApril 15, 2024 | finance.yahoo.comCarl Zeiss Meditec AG (AFX.HA)March 28, 2024 | msn.comReachTV Names First-Ever President Bob Gruters; Hires Andrew Eisner As EVP Sales & PartnershipsApril 19, 2024 | Stansberry Research (Ad)Strange new buyer driving up goldOne Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."March 28, 2024 | finanznachrichten.deCarl Zeiss Meditec AG: ZEISS Sets Stage for Future of Ophthalmic Surgery and 3D Visualization at ASCRS 2024March 28, 2024 | finance.yahoo.comZEISS Sets Stage for Future of Ophthalmic Surgery and 3D Visualization at ASCRS 2024March 16, 2024 | barrons.comCarl Zeiss Meditec AGFebruary 20, 2024 | au.finance.yahoo.comCarl Zeiss Meditec AG (AFX.DE)February 4, 2024 | au.finance.yahoo.comCarl Zeiss Meditec AG (AFX.SW)April 19, 2024 | Stansberry Research (Ad)Strange new buyer driving up goldOne Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."February 2, 2024 | uk.investing.comCarl Zeiss Meditec AG ADR (CZMWY)December 11, 2023 | finance.yahoo.comThe Return Trends At Carl Zeiss Meditec (ETR:AFX) Look PromisingOctober 28, 2023 | morningstar.comCarl Zeiss Meditec AG AFXOctober 17, 2023 | finance.yahoo.comThe past three years for Carl Zeiss Meditec (ETR:AFX) investors has not been profitableOctober 2, 2023 | finanznachrichten.deCarl Zeiss Meditec AG: ZEISS and Boehringer Ingelheim join forces to develop early detection of eye diseases and prevent vision lossSeptember 22, 2023 | finance.yahoo.comCarl Zeiss Meditec AG's (ETR:AFX) 4.0% loss last week hit both individual investors who own 59% as well as institutionsJuly 18, 2023 | finance.yahoo.comDo Carl Zeiss Meditec's (ETR:AFX) Earnings Warrant Your Attention?July 15, 2023 | uk.finance.yahoo.comAFX.DE - Carl Zeiss Meditec AGMay 10, 2023 | markets.businessinsider.comCarl Zeiss Meditec H1 Profit Down, Revenues Rise; Backs FY23 Outlook - Quick FactsMay 10, 2023 | markets.businessinsider.comEQS-News: Carl Zeiss Meditec achieves double-digit growth in first half year of 2022/23 with declining earningsMay 10, 2023 | finance.yahoo.comCarl Zeiss Meditec (ETR:AFX) sheds 8.7% this week, as yearly returns fall more in line with earnings growthMarch 29, 2023 | finance.yahoo.comDoes This Valuation Of Carl Zeiss Meditec AG (ETR:AFX) Imply Investors Are Overpaying?February 4, 2023 | finance.yahoo.comWith EPS Growth And More, Carl Zeiss Meditec (ETR:AFX) Makes An Interesting CaseDecember 29, 2022 | finance.yahoo.comCarl Zeiss Meditec (ETR:AFX) Is Paying Out A Larger Dividend Than Last YearDecember 1, 2022 | finance.yahoo.comCarl Zeiss Meditec's (ETR:AFX) five-year total shareholder returns outpace the underlying earnings growthNovember 17, 2022 | finance.yahoo.comWhen Should You Buy Carl Zeiss Meditec AG (ETR:AFX)?November 1, 2022 | finance.yahoo.comPrivate companies who hold 59% of Carl Zeiss Meditec AG (ETR:AFX) gained 4.3%, institutions profited as wellAugust 31, 2022 | finanznachrichten.deCarl Zeiss Meditec AG: ZEISS Integrated Workflow Solutions are Creating the Digital Transformation in HealthcareSee More Headlines Receive AFX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Carl Zeiss Meditec and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeETR SectorMedical Industry Medical Instruments & Supplies Sub-IndustryN/A Current SymbolETR:AFX CUSIPN/A CIKN/A Webwww.zeiss.com Phone+49-3641-2200FaxN/AEmployees4,823Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)€3.10 Trailing P/E Ratio31.50 Forward P/E Ratio32.37 P/E Growth3.86Net Income$276.80 million Net Margins13.22% Pretax MarginN/A Return on Equity13.24% Return on Assets7.55% Debt Debt-to-Equity Ratio7.16 Current Ratio3.40 Quick Ratio2.47 Sales & Book Value Annual Sales$2.09 billion Price / Sales4.18 Cash Flow€0.07 per share Price / Cash Flow1,398.28 Book Value€24.14 per share Price / Book4.05Miscellaneous Outstanding Shares89,440,000Free FloatN/AMarket Cap$8.73 billion OptionableNot Optionable Beta0.92 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Markus WeberCEO & Chairman of Management BoardMr. Justus Felix Wehmer (Age 59)CFO & Member of the Management Board Comp: $609.4kDr. Christian Munster (Age 53)Head of Global Regulatory & Clinical Affairs, CoCe Site Jena & Emp. Rep. Member of Supervisory Board Stefanie SpanagelChief Operating OfficerMr. Sebastian FrericksDirector of Investor RelationsEva-Maria HeineChief Human Resources OfficerMr. Steven C. Schallhorn M.D.Chief Medical Officer for Global Ophthalmic DevicesMr. Andrew ChangHead of Sales for Ophthalmic Devices & President of Carl Zeiss Meditec, Inc.Dr. Euan S. Thomson Ph.D. (Age 61)President of Ophthalmic Devices and Head of the Ophthalmic Devices Strategic & Digital Business Unit Mr. Magnus ReibenspiessHead of the Microsurgery Strategic Business Unit - ZEISS Medical TechnologyMore ExecutivesKey CompetitorsSartorius AktiengesellschaftETR:SRTGerresheimerETR:GXIFresenius Medical CareETR:FMEMorphoSysETR:MOREvotecETR:EVTView All Competitors AFX Stock Analysis - Frequently Asked Questions How have AFX shares performed in 2024? Carl Zeiss Meditec's stock was trading at €98.84 at the beginning of the year. Since then, AFX stock has decreased by 1.2% and is now trading at €97.65. View the best growth stocks for 2024 here. Is Carl Zeiss Meditec a good dividend stock? Carl Zeiss Meditec (ETR:AFX) pays an annual dividend of €1.10 per share and currently has a dividend yield of 0.92%. The dividend payout ratio is 35.48%. This payout ratio is at a healthy, sustainable level, below 75%. What other stocks do shareholders of Carl Zeiss Meditec own? Based on aggregate information from My MarketBeat watchlists, some companies that other Carl Zeiss Meditec investors own include Covestro (1COV), AbbVie (ABBV), Allianz (ALV), Daimler (DAI), Gilead Sciences (GILD), Intel (INTC), NVIDIA (NVDA), QUALCOMM (QCOM) and SAP (SAP). This page (ETR:AFX) was last updated on 4/19/2024 by MarketBeat.com Staff From Our PartnersThe “Perfect Storm” for GoldGold Safe ExchangeThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingBiden’s $374B Giveaway Into This SectorDTIYour Money is Not SafeAmerican AlternativeHe Is Giving Away BitcoinCrypto Swap ProfitsThe #1 Crypto for 2024InvestorPlaceSHOCKING Crypto Leak…Crypto 101 MediaMy biggest AI fearParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Carl Zeiss Meditec AG Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.